3973-53-3

Upstream product

• 3973-52-2 [2-(4-bromophenyl)ethyl]benzoic acid 
• 85-44-9 phthalic anhydride 
• 3979-66-6 3-(4-bromobenzylidene)isobenzofuran-1-(3H)-one 
• 191999-28-7 (Z)-3-(4-bromobenzylidene)isobenzofuran-1(3H)-one 
• 1446114-05-1 methyl 5-bromo-2-(phenylethynyl)benzoate 
• 942273-02-1 C₁₅H₁₃BrO₂ 
• 1448704-65-1 methyl 5-bromo-2-trimethylsilylethynylbenzoate 
• 181765-86-6 5-bromo-2-iodo-benzoic acid methyl ester 
• 1446114-07-3 2-ethynyl-5-bromobenzoic acid methyl ester 
• 1210-35-1 10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-one 
• 1446114-02-8 methyl 5-bromo-2-phenethylbenzoate 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 

Downstream Products

• 463347-88-8 5-bromo-2,2'-bis(hydroxymethyl)diphenylmethane 
• 4260-63-3 3-Carboxy-5-methyl-5H-dibenzo-cyclohepten-5-ol 

Relevant academic research and scientific papers

SPIRALLY CONFIGURED CIS-STILBENE/FLUORENE HYBRID MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME

A spirally configured cis-stilbene/fluorene hybrid material is shown in formula (1), wherein n is 1, 2 or 3, R1 to R6 are independently selected from the group consisting of hydrogen atom, halogen atom, cyano group, alkyl group, cycl

Synthesis of a human urate transporter-1 inhibitor, an arginine vasopressin antagonist, and a 17β-hydroxysteroid dehydrogenase type-3 inhibitor, using ring-expansion of cyclic ketoximes with DIBALH

Synthesis of three clinical candidates for medicines, a human urate transporter-1 inhibitor, an arginine vasopressin antagonist, and a 17β-hydroxysteroid dehydrogenase type-3 inhibitor, is described. These compounds were synthesized via construction of their 3,4-dihydro-2H-benzo[b][1, 4]oxazine, dibenzodiazepine, and dibenzazocine skeletons, respectively, using the reductive ring-expansion reaction of the corresponding bicyclic or tricyclic oximes with diisobutylaluminum hydride.

Construction of Dibenzazocine Skeleton by Regiocontrolled Ring-Expansion Reaction of Cyclic Oxime with DIBAL-H: Facile Synthesis of 17β-Hydroxy- steroid Dehydrogenase Type 3 Inhibitor

Synthetic studies on a 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) inhibitor are described. The unsymmetrical dibenzazocine skeleton was constructed by a regiocontrolled ring-expansion reaction of a cyclic oxime with DIBAL-H. Georg Thieme Verlag Stuttgart · New York.

The first efficient synthesis and optical resolution of monosubstituted cyclotribenzylenes

A new and high yielding synthetic route to monosubstituted cyclotribenzylenes 6 via the cyclocondensation of benzene with a suitably monosubstituted diol 20, obtained from ozonolysis of the corresponding dibenzosuberene precursor 19, was developed for the first time! The dibenzosuberene itself could be readily prepared in large quantities from inexpensive starting materials in five steps. Using this synthetic approach, a mono bromosubstituted cyclotribenzylene 12a was synthesized on large scale. Another four monosubstituted cyclotribenzylenes 21-24 were also prepared either via bromine/lithium exchange followed by subsequent quenching with external electrophiles or a copper mediated reaction with cyanide. These molecules adopt a rigid crown conformation as shown by X-ray analysis and temperature dependent NMR studies. The barrier to inversion is quite high, requiring temperatures well above 120°C before inversion takes place. Futhermore, such monosubstituted cyclotribenzylenes are planar chiral and after optical resolution, using HPLC, we were able to obtain the first planar chiral Cl-symmetric cyclotribenzylenes in form of the optically pure enantiomers of 12a, the CD spectra of which are exact mirror images over the entire spectral range.

Synthesis of new substituted dibenzosuberones

The multistep synthesis of new monosubstituted amides of dibenzosuberone series is described starting from 3-bromobenzosuberone; N-(3- dimethylaminopropyl)- 10,11 -dihydro-5H-dibenzo[a,d]cycloheptene-5-one- 3carboxamide 4 and N-(3-dimethylaminopropyl)-3-chloro-dibenzosuberonyl [4',12'-b]thiophene-2-carboxamide 7.

Tricyclic compounds

Novel tricyclic compounds having a TXA2 -antagonizing activity represented by formula (I): STR1 which strongly antagonize an action of thromboxane A2 and are expected to have preventive and therapeutic effects on ischemica diseases, cerebro-vascular diseases, etc.